In a comparison of outcomes for out-of-hospital cardiopulmonary resuscitation (CPR) for cardiac arrest performed by bystanders, patients who received compression-only CPR were more likely to survive to hospital discharge than patients who received conventional CPR or no CPR, according to a study….
Read More »Diabetes Risk Falls as Magnesium Intake Increases
Getting enough magnesium in your diet could help prevent diabetes, a new study suggests. Consuming 200 milligrams of magnesium for every 1,000 calories reduces risk of diabetes by 47%….
Read More »EASD: Adding Incretin to Insulin Lowers HbA1c
Adding exenatide to insulin glargine for patients who aren’t fully controlled with insulin glargine and/or other oral agents can help to improve their blood glucose….
Read More »EASD: Preliminary Study Shows: Early Routine Diabetes Treatment Works as Well as Early Intensive Therapy
Early treatment of screen-detected Type 2 diabetes works regardless of how intensively glucose, lipids, and blood pressure are managed, experts concluded on the basis of a large randomized trial presented….
Read More »EASD: Continuous Monitors May Miss Hypoglycemia
Continuous blood glucose monitors may not accurately detect low blood sugar, researchers found….
Read More »EASD: Frequent Hypoglycemia Key in Cardiac Risk
Patients with Type 1 diabetes who have repeated episodes of hypoglycemia appear to be at risk for early signs of atherosclerosis, researchers said….
Read More »EASD: Pioglitazone-Sitagliptin Combination Achieves Durable Glycemic Control
Adding 50 mg of sitagliptin (Januvia) to pioglitazone (Actos) allowed patients with Type 2 diabetes to achieve sustained glycemic control, a yearlong trial showed….
Read More »EASD: New Drug Classes Entering Type 2 Pipeline
Farnesoid X receptor agonists, 11-β-HSD1 inhibitors, and glucokinase activators are some of the new approaches to treating Type 2 diabetes described in research presented, but some senior researchers expressed doubts about the clinical need for them….
Read More »EASD: Once-Weekly Exenatide Benefit Sustained over 52 Weeks
Once-Weekly Exenatide maintains a drop in A1c of 2 points for more than 52 weeks….
Read More »EASD: Legacy of Early Intensive Glucose Control Lasts a Decade
Intensive glucose control even after 10 years still shows clinical benefits and even rises over time….
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.